The FDA approval of daraxonrasib (Rasonque), an oral RAS(ON) inhibitor employing a mechanism that has long been difficult to achieve, for patients with metastatic pancreatic adenocarcinoma provides a new treatment option after prior systemic therapy,... [10080 chars]
